Amgen Inc. $AMGN Shares Sold by Elevated Capital Advisors LLC

Elevated Capital Advisors LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 64.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 654 shares of the medical research company’s stock after selling 1,211 shares during the quarter. Elevated Capital Advisors LLC’s holdings in Amgen were worth $276,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. grew its stake in Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after buying an additional 2,261,544 shares during the last quarter. State Street Corp lifted its position in Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after acquiring an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Amgen by 12.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after acquiring an additional 605,928 shares during the last quarter. Bank of America Corp DE acquired a new position in Amgen during the 2nd quarter worth $1,831,903,000. Finally, Amundi boosted its holdings in Amgen by 15.2% during the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after acquiring an additional 512,883 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Amgen Stock Performance

Shares of AMGN stock opened at $465.23 on Wednesday. The firm has a market capitalization of $251.65 billion, a P/E ratio of 26.99, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43. Amgen Inc. has a 1 year low of $312.39 and a 1 year high of $483.99. The firm’s fifty day simple moving average is $423.79 and its 200 day simple moving average is $379.39. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business’s revenue was up 8.5% on a year-over-year basis. During the same period in the prior year, the firm earned $5.64 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 23.33 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio is currently 58.47%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on AMGN shares. Oppenheimer reaffirmed an “outperform” rating on shares of Amgen in a research report on Friday, October 23rd. Scotiabank lifted their price objective on Amgen from $500.00 to $530.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, November 4th. Cantor Fitzgerald boosted their price objective on Amgen from $440.00 to $465.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 4th. Jefferies Financial Group restated a “hold” rating and set a $410.00 target price on shares of Amgen in a research note on Wednesday, September 23rd. Finally, Citigroup increased their target price on Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus target price of $422.76.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.